Literature DB >> 24787503

Relation between clinical findings and progression of cerebral cortical pathology in MM1-type sporadic Creutzfeldt-Jakob disease: proposed staging of cerebral cortical pathology.

Yasushi Iwasaki1, Shinsui Tatsumi2, Maya Mimuro2, Tetsuyuki Kitamoto3, Yoshio Hashizume4, Mari Yoshida2.   

Abstract

In our pathologic observation of the cerebral cortex including the neocortex, hippocampus, and limbic cortex in 43 Japanese patients with MM1-type sporadic Creutzfeldt-Jakob disease, the earliest pathologic finding was spongiform change and next was gliosis. Subsequently, neuropil rarefaction appeared, followed by neuron loss. On the basis of these observations, we propose the following cortical pathologic staging: Stage I, spongiform change; Stage II, hypertrophic astrocytosis; Stage III, neuropil rarefaction; Stage IV, neuron loss; Stage V, status spongiosus; and Stage VI, large cavity formation. We also suggest a more simple staging classification: Stages I and II, mild; Stages III and IV, moderate; and Stages V and VI, severe involvement. Based on statistical analysis of the cases, strong correlation coefficients were obtained between the neocortical and limbic pathologic stage and both total disease duration and brain weight. We estimated that the first observation times of cortical hyperintensity on diffusion-weighted images of magnetic resonance imaging, myoclonus, and periodic sharp wave complexes on the electroencephalogram approximately correspond to the early phase of Stage II of the neocortex. The time to reach the akinetic mutism state approximately corresponds to the middle phase of Stage II of the neocortex. Therefore, we think that approximate clinical manifestations at death, total disease duration, and brain weight can be estimated according to the pathologic stage of the neocortex or limbic cortex. Panencephalopathic-type pathology appeared approximately 12 months after disease onset, and this time approximately corresponds to the middle phase of Stage III of the neocortex.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Creutzfeldt–Jakob disease; Hypertrophic astrocytosis; Neuron loss; Neuropil rarefaction; Spongiform change

Mesh:

Year:  2014        PMID: 24787503     DOI: 10.1016/j.jns.2014.04.011

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  6 in total

1.  Autopsy-like MRI findings: report on Creutzfeldt-Jakob disease in the end-stage.

Authors:  Simona Cammaroto; Chiara Smorto; Danilo Galletta; Placido Bramanti; Rocco Salvatore Calabrò
Journal:  Neurol Sci       Date:  2015-02-18       Impact factor: 3.307

2.  Pathological progression of genetic Creutzfeldt-Jakob disease with a PrP V180I mutation.

Authors:  Akio Akagi; Yasushi Iwasaki; Maya Mimuro; Tetsuyuki Kitamoto; Masahito Yamada; Mari Yoshida
Journal:  Prion       Date:  2018-01-31       Impact factor: 3.931

Review 3.  Detection of Pathognomonic Biomarker PrPSc and the Contribution of Cell Free-Amplification Techniques to the Diagnosis of Prion Diseases.

Authors:  Hasier Eraña; Jorge M Charco; Ezequiel González-Miranda; Sandra García-Martínez; Rafael López-Moreno; Miguel A Pérez-Castro; Carlos M Díaz-Domínguez; Adrián García-Salvador; Joaquín Castilla
Journal:  Biomolecules       Date:  2020-03-19

4.  Clinicopathological findings of a long-term survivor of V180I genetic Creutzfeldt-Jakob disease.

Authors:  Yuichi Hayashi; Yasushi Iwasaki; Masahiro Waza; Shinei Kato; Akio Akagi; Akio Kimura; Takashi Inuzuka; Katsuya Satoh; Tetsuyuki Kitamoto; Mari Yoshida; Takayoshi Shimohata
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

5.  Analysis of Chinese patients with sporadic Creutzfeldt-Jakob disease.

Authors:  Jing Yang; Haiyan Kuang; Qiong Wang; Jiao Liu; Xueping Chen; Huifang Shang
Journal:  Prion       Date:  2020-12       Impact factor: 3.931

6.  System degeneration in an MM1-type sporadic Creutzfeldt-Jakob disease case with an unusually prolonged akinetic mutism state.

Authors:  Yasushi Iwasaki; Keiko Mori; Masumi Ito; Yoshinari Kawai; Akio Akagi; Yuichi Riku; Hiroaki Miyahara; Atsushi Kobayashi; Tetsuyuki Kitamoto; Mari Yoshida
Journal:  Prion       Date:  2021-12       Impact factor: 3.931

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.